164 related articles for article (PubMed ID: 16925490)
1. Role of PET/PET-CT in the management of sarcomas.
Kumar R; Chauhan A; Vellimana AK; Chawla M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1241-50. PubMed ID: 16925490
[TBL] [Abstract][Full Text] [Related]
2. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
Bestic JM; Peterson JJ; Bancroft LW
Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET-CT in soft tissue sarcomas: staging, restaging, and prognostic value?
Gabriel M; Rubello D
Nucl Med Commun; 2016 Jan; 37(1):3-8. PubMed ID: 26457597
[TBL] [Abstract][Full Text] [Related]
5. The use of fluorine-18 fluorodesoxyglycose-positron emission tomography for treatment monitoring in patients with soft tissue sarcomas.
Kasper B; Hohenberger P; Strauss LG; Dimitrakopoulou-Strauss A
Hell J Nucl Med; 2010; 13(1):40-4. PubMed ID: 20411170
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of positron emission tomography-computed tomography in oncology.
Kumar R; Halanaik D; Malhotra A
Indian J Cancer; 2010; 47(2):100-19. PubMed ID: 20448371
[TBL] [Abstract][Full Text] [Related]
7. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
[TBL] [Abstract][Full Text] [Related]
8. Clinical applications of positron emission tomography in sarcoma management.
Quak E; van de Luijtgaarden AC; de Geus-Oei LF; van der Graaf WT; Oyen WJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):195-204. PubMed ID: 21342039
[TBL] [Abstract][Full Text] [Related]
9. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
[TBL] [Abstract][Full Text] [Related]
11. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
12. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
13. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
Peterson JJ
Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
[TBL] [Abstract][Full Text] [Related]
14. PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
Endo K; Oriuchi N; Higuchi T; Iida Y; Hanaoka H; Miyakubo M; Ishikita T; Koyama K
Int J Clin Oncol; 2006 Aug; 11(4):286-96. PubMed ID: 16937302
[TBL] [Abstract][Full Text] [Related]
15. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
16. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
17. Quantitative dynamic ¹⁸FDG-PET and tracer kinetic analysis of soft tissue sarcomas.
Rusten E; Rødal J; Revheim ME; Skretting A; Bruland OS; Malinen E
Acta Oncol; 2013 Aug; 52(6):1160-7. PubMed ID: 23198721
[TBL] [Abstract][Full Text] [Related]
18. (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of recurrent bone and soft tissue sarcoma.
Al-Ibraheem A; Buck AK; Benz MR; Rudert M; Beer AJ; Mansour A; Pomykala KL; Haller B; Juenger H; Scheidhauer K; Schwaiger M; Herrmann K
Cancer; 2013 Mar; 119(6):1227-34. PubMed ID: 23233156
[TBL] [Abstract][Full Text] [Related]
19. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study.
Iagaru A; Mittra E; Yaghoubi SS; Dick DW; Quon A; Goris ML; Gambhir SS
J Nucl Med; 2009 Apr; 50(4):501-5. PubMed ID: 19289439
[TBL] [Abstract][Full Text] [Related]
20. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]